CDK9 and hematopoietic and lymphoid cell neoplasm: A structure-based approach led to the identification of AZD4573, a highly potent CDK9 inhibitor with over 25-fold selectivity for CDK9 over other CDKs, and broad antitumor activity across preclinical hematologic cancer models [80, 81].